Removing the Squeeze on Clinical Operations through Transparency, Integration and Automation
From reporting challenges to data integration and data silos with ...
Connected to the Future: Making Drug Safety Databases Transparent, E2B R3 Compliant and Cost-Effective
As different regulatory authorities have different timelines for adoption of these standards, E2B(R2) E2B(R3) will have to coexist. But having to operate two solutions creates huge complexities, unless you find a solution compliant with both. ArisGlobal LifeSphere Safety MultiVigilance is the only drug safety database solution provider thus far to provide full compliance to E2B R2 and E2B R3 standards for both import and export.
Blog: Automation in ICSR Processing – Is Artificial Intelligence the Paradigm Shift in Pharmacovigilance?
Artificial intelligence (AI), machine learning, deep learning, natural language processing ...
Breaking Down Silos across the Life Sciences Enterprise Helps Drive Innovation
Silos have long plagued the life sciences industry, and nowhere ...
Removing the Pain Points from Overburdened Medical Affairs Teams
Today’s Medical Information (MI) and Medical Affairs professionals are juggling ...
Enabling an Evidence-Based Approach to Pharmacovigilance and Safety
Safety departments at Marketing Authorization Holders & Regulatory Authorities are ...
The Search for Simplicity, Scalability and Timely Insights in Regulatory Affairs
Rising Expectations from Regulatory Affairs Executives As we all know ...
Automation in Pharmacovigilance Data Processing – Do You Trust Artificial Intelligence?
Artificial intelligence (AI), machine learning, deep learning, natural language processing – in short, cognitive computing, is changing the pharmacovigilance world as we know it. While there’s a lot of talk about how AI will affect jobs, where it will have the most powerful impact is on the quality of work and the speed at which manual tasks can be accomplished.
ArisGlobal Viewpoint: How Digitization Changes the Role of Regulatory Affairs
This is the last in the ArisGlobal three-part blog series on Regulatory Affairs transformation. Digitization is sweeping the life sciences industry, disrupting traditional working practices and opening doors to better ways of collaborating, tracking and sharing documents and data, and gaining clear oversight into the product supply chain.
ArisGlobal Expert Shares How Regulatory Affairs Needs to Adapt to Transformation Change
The life sciences industry is confronting a wave of transformational change, brought about by multiple factors, including the growth of new clinical trial markets, a rapid rise in drug development innovation, reimbursement challenges, heightened regulatory requirements and a demand for evidence-based medicine, among many others. These drivers and the resultant changes are having a profound effect on regulatory affairs.
